» Articles » PMID: 16507989

Normal Cells, but Not Cancer Cells, Survive Severe Plk1 Depletion

Overview
Journal Mol Cell Biol
Specialty Cell Biology
Date 2006 Mar 2
PMID 16507989
Citations 139
Authors
Affiliations
Soon will be listed here.
Abstract

We previously reported the phenotype of depletion of polo-like kinase 1 (Plk1) using RNA interference (RNAi) and showed that p53 is stabilized in Plk1-depleted cancer cells. In this study, we further analyzed the Plk1 depletion-induced phenotype in both cancer cells and primary cells. The vector-based RNAi approach was used to evaluate the role of the p53 pathway in Plk1 depletion-induced apoptosis in cancer cells with different p53 backgrounds. Although DNA damage and cell death can occur independently of p53, p53-deficient cancer cells were much more sensitive to Plk1 depletion than cancer cells with functional p53. Next, the lentivirus-based RNAi approach was used to generate a series of Plk1 hypomorphs. In HeLa cells, two weak hypomorphs showed only slight G2/M arrest, a medium hypomorph arrested with 4N DNA content, followed later by apoptosis, and a strong Plk1 hypomorph underwent serious mitotic catastrophe. In well-synchronized HeLa cells, a medium level of Plk1 depletion caused a 2-h delay of mitotic progression, and a high degree of Plk1 depletion significantly delayed mitotic entry and completely blocked cells at mitosis. In striking contrast, normal hTERT-RPE1 and MCF10A cells were much less sensitive to Plk1 depletion than HeLa cells; no apparent cell proliferation defect or cell cycle arrest was observed after Plk1 depletion in these cells. Therefore, these data further support suggestions that Plk1 may be a feasible cancer therapy target.

Citing Articles

Polo-like Kinase 1 Inhibitors Demonstrate In Vitro and In Vivo Efficacy in Preclinical Models of Small Cell Lung Cancer.

Zhang G, Pannucci A, Ivanov A, Switchenko J, Sun S, Sica G Cancers (Basel). 2025; 17(3).

PMID: 39941812 PMC: 11815996. DOI: 10.3390/cancers17030446.


Elevating PLK1 overcomes BETi resistance in prostate cancer via triggering BRD4 phosphorylation-dependent degradation in mitosis.

Zhang Y, Fong K, Mao F, Wang R, Allison D, Napier D Cell Rep. 2024; 43(7):114431.

PMID: 38968071 PMC: 11334074. DOI: 10.1016/j.celrep.2024.114431.


PLK1 inhibition leads to mitotic arrest and triggers apoptosis in cholangiocarcinoma cells.

Moolmuang B, Chaisaingmongkol J, Singhirunnusorn P, Ruchirawat M Oncol Lett. 2024; 28(1):316.

PMID: 38807667 PMC: 11130613. DOI: 10.3892/ol.2024.14449.


Multifunctional Fluoropolymer-Engineered Magnetic Nanoparticles to Facilitate Blood-Brain Barrier Penetration and Effective Gene Silencing in Medulloblastoma.

Forgham H, Zhu J, Huang X, Zhang C, Biggs H, Liu L Adv Sci (Weinh). 2024; 11(25):e2401340.

PMID: 38647396 PMC: 11220643. DOI: 10.1002/advs.202401340.


Genetic enhancers of partial PLK1 inhibition reveal hypersensitivity to kinetochore perturbations.

Normandin K, Coulombe-Huntington J, St-Denis C, Bernard A, Bourouh M, Bertomeu T PLoS Genet. 2023; 19(8):e1010903.

PMID: 37639469 PMC: 10491399. DOI: 10.1371/journal.pgen.1010903.


References
1.
Strebhardt K, Kneisel L, Linhart C, Bernd A, Kaufmann R . Prognostic value of pololike kinase expression in melanomas. JAMA. 2000; 283(4):479-80. DOI: 10.1001/jama.283.4.479. View

2.
Eckerdt F, Yuan J, Strebhardt K . Polo-like kinases and oncogenesis. Oncogene. 2005; 24(2):267-76. DOI: 10.1038/sj.onc.1208273. View

3.
Donaldson M, TAVARES A, Ohkura H, Deak P, Glover D . Metaphase arrest with centromere separation in polo mutants of Drosophila. J Cell Biol. 2001; 153(4):663-76. PMC: 2192380. DOI: 10.1083/jcb.153.4.663. View

4.
Takai N, Hamanaka R, Yoshimatsu J, Miyakawa I . Polo-like kinases (Plks) and cancer. Oncogene. 2005; 24(2):287-91. DOI: 10.1038/sj.onc.1208272. View

5.
Gumireddy K, Reddy M, Cosenza S, Boominathan R, Boomi Nathan R, Baker S . ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell. 2005; 7(3):275-86. DOI: 10.1016/j.ccr.2005.02.009. View